Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
June 2017
-
Press release
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared… -
Story From Our Labs
Minion challenges assumptions about the genome
A diminutive protein prompts a closer look at DNA dark matter.
May 2017
-
Press release
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process… -
Press release
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data… -
Press release
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become… -
Press release
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the… -
Press release
Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate… -
Story Discovery
Going global to meet local needs in China
Marc Pelletier traveled from Cambridge, MA to Shanghai, China, to launch new lines of research for the treatment of cancers that are common in China.
-
Story Patient Perspectives
Choosing the right care
Melanoma survivor T.J. Sharpe shares why patients should know their treatment options.
-
Press release
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of… -
Press release
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]… -
Press release
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…